Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.86 +3.1%	$4.98	$3.62 ▼ $9.33	$918.39M	0.76	4.38 million shs	2.25 million shs
CYRX Cryoport	$5.63 -2.8%	$5.80	$4.58 ▼ $16.89	$279.51M	1.92	543,320 shs	70,510 shs
MESO Mesoblast	$11.04 -2.3%	$12.35	$5.78 ▼ $22.00	$1.41B	2.5	270,133 shs	16,858 shs
RCKT Rocket Pharmaceuticals	$7.38 -5.9%	$7.34	$4.55 ▼ $26.98	$790.22M	1.02	1.36 million shs	334,692 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-9.69%	-30.28%	-18.02%	-32.43%	-57.22%
CYRX Cryoport	-1.19%	+1.58%	+8.43%	-17.17%	-63.70%
MESO Mesoblast	-6.22%	-0.96%	+6.91%	-44.61%	+50.67%
RCKT Rocket Pharmaceuticals	-2.00%	+9.64%	+53.32%	-29.15%	-66.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.4931 of 5 stars	4.5	2.0	4.4	2.3	2.5	0.6
CYRX Cryoport	3.1406 of 5 stars	4.4	1.0	0.0	2.6	3.3	0.6
MESO Mesoblast	1.6564 of 5 stars	3.5	2.0	0.0	1.3	0.8	0.6
RCKT Rocket Pharmaceuticals	4.7214 of 5 stars	4.5	1.0	4.7	2.8	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.90	Moderate Buy	$10.39	169.49% Upside
CYRX Cryoport	2.71	Moderate Buy	$11.00	95.56% Upside
MESO Mesoblast	3.00	Buy	$18.00	63.04% Upside
RCKT Rocket Pharmaceuticals	2.92	Moderate Buy	$43.00	482.42% Upside

Current Analyst Ratings Breakdown

Latest CYRX, RCKT, ARDX, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/5/2025	CYRX Cryoport	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $7.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
4/16/2025	CYRX Cryoport	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/16/2025	CYRX Cryoport	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/10/2025	CYRX Cryoport	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/9/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/1/2025	CYRX Cryoport	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/1/2025	CYRX Cryoport	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $11.00
3/31/2025	CYRX Cryoport	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/31/2025	MESO Mesoblast	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.62M	2.75	N/A	N/A	$0.73 per share	5.28
CYRX Cryoport	$228.39M	1.23	$0.33 per share	16.95	$9.45 per share	0.60
MESO Mesoblast	$5.67M	248.80	N/A	N/A	$4.21 per share	2.62
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	12.44	N/A	-11.73%	-24.87%	-10.51%	N/A
CYRX Cryoport	-$99.59M	-$2.49	N/A	N/A	N/A	-70.08%	-13.35%	-6.43%	5/7/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.73	N/A	N/A	N/A	N/A	-62.62%	-54.17%	N/A

Latest CYRX, RCKT, ARDX, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	CYRX Cryoport	-$0.28	N/A	N/A	N/A	$56.19 million	N/A
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million
3/4/2025	Q4 2024	CYRX Cryoport	-$0.33	-$0.42	-$0.09	-$0.42	$58.71 million	$59.53 million
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A
2/20/2025	Q4 2024	ARDX Ardelyx	$0.02	$0.02	N/A	$0.02	$111.16 million	$116.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
CYRX Cryoport	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	0.87	4.58	4.31
CYRX Cryoport	0.48	5.70	5.32
MESO Mesoblast	0.21	1.18	1.18
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
CYRX Cryoport	92.90%
MESO Mesoblast	1.43%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.90%
CYRX Cryoport	10.10%
MESO Mesoblast	18.80%
RCKT Rocket Pharmaceuticals	28.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	238.36 million	222.88 million	Optionable
CYRX Cryoport	1,020	50.14 million	44.44 million	Optionable
MESO Mesoblast	80	127.78 million	103.17 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

CYRX, RCKT, ARDX, and MESO Headlines

Recent News About These Companies

Avidity Partners Management LP Boosts Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 6 at 7:39 AM | marketbeat.com

Baker BROS. Advisors LP Buys Shares of 97,079 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 6 at 7:39 AM | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Moderate Buy" by Analysts

May 5 at 2:31 AM | marketbeat.com

Rocket Lab Wins Share of a $46 Billion Defense Contract. How Big a Share? Well...

May 4 at 10:34 AM | aol.com

Acuta Capital Partners LLC Decreases Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 4 at 7:13 AM | marketbeat.com

Boxer Capital Management LLC Makes New Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 4 at 6:25 AM | marketbeat.com

Rocket Pharmaceuticals (RCKT) Expected to Announce Earnings on Monday

May 4 at 2:25 AM | americanbankingnews.com

Price T Rowe Associates Inc. MD Sells 59,261 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 2, 2025 | marketbeat.com

Rocket Pharmaceuticals (RCKT) to Release Earnings on Monday

April 30, 2025 | marketbeat.com

Renaissance Technologies LLC Acquires Shares of 218,519 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

April 27, 2025 | marketbeat.com

48,400 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Bought by Natixis

April 26, 2025 | marketbeat.com

Marshall Wace LLP Purchases 446,662 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

April 26, 2025 | marketbeat.com

Rocket Lab USA takes aim at SpaceX with Neutron Rocket

April 25, 2025 | msn.com

Tickets to Rocket Classic, Detroit's PGA Tour stop, now on sale

April 25, 2025 | detroitnews.com

Warriors' Steve Kerr shares disappointment in Rocket's fans chants toward Draymond Green

April 25, 2025 | msn.com

Red Rocket starts operations at two 144 MW wind farms

April 25, 2025 | engineeringnews.co.za

Rocket Report: The pitfalls of rideshare; China launches next Tiangong crew

April 25, 2025 | arstechnica.com

Why Is Rocket Lab Stock Trading Higher On Thursday?

April 24, 2025 | benzinga.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 3.6% - Time to Sell?

April 24, 2025 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 8.9% - Here's What Happened

April 23, 2025 | marketbeat.com

Avoro Capital Advisors LLC Buys New Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

April 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX, RCKT, ARDX, and MESO Company Descriptions

Ardelyx NASDAQ:ARDX

$3.86 +0.12 (+3.07%)

As of 10:59 AM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Cryoport NASDAQ:CYRX

$5.62 -0.17 (-2.85%)

As of 10:59 AM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Mesoblast NASDAQ:MESO

$11.04 -0.26 (-2.30%)

As of 10:56 AM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Rocket Pharmaceuticals NASDAQ:RCKT

$7.38 -0.47 (-5.95%)

As of 10:59 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time